RapidPulse, Inc., a medical technology company developing next-generation aspiration technology for the treatment of acute ischemic stroke, today announced the close of a $48 million Series B financing. The raise, which drew substantial investor interest, was co-led by Medtronic, TechWald Next S.p.A., and S3 Ventures. SBI Investment Company Ltd. and Florida Opportunity Fund also joined previous investors Santé Ventures, Syntheon, Hatteras Venture Partners, and Epidarex Capita

Canary Speech, a leader in AI-powered voice biomarker technology, and NeuroLexIQ, The Brain Injury Authority, today announced a strategic partnership to bring objective, voice-based concussion screening into the earliest moment of a personal injury case: the client's first intake call. Mild traumatic brain injuries, or mTBIs, are among the most under-documented injuries in personal injury litigation. Every year, thousands of people walk away from car crashes and falls with concu

InterSystems, a creative data technology provider powering more than one billion health records globally, today announced it has been recognised as a Leader in the 2026 Gartner Magic Quadrant for Enterprise Electronic Health Records (EHR). A Gartner Magic Quadrant is a culmination of research in a specific market, giving you a wide-angle view of the relative positions of the market’s competitors. By applying a graphical treatment and a uniform set of evaluation criteria, a Mag

Switchboard, MD today announced it has joined athenahealth's Partner Community as a Solution Partner. Its solution is now available in the athenahealth Marketplace, providing access to athenahealth's growing network of healthcare providers. The new integration enables healthcare providers to automatically turn every inbound referral into scheduled appointments and procedures, dramatically increasing revenue while reducing administrative burden. Switchboard, MD captures refer

Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has been granted Canadian Patent No. 3,158,197, titled "Endoscopic Sympathectomy Systems and Methods." The Company’s growing global intellectual property portfolio now includes 112 issued or pending patent applications worldwide with the newest patent further strengthening the

Longeviti Neuro Solutions, a neurotechnology company focused on advancing innovative solutions that unlock post-operative ultrasound access to the brain, today announced the launch of two strategic initiatives, ClearFit AI™, a Brain Ultrasound Interface (BUI). Together, these technologies create a persistent acoustic interface to the brain, enabling real-time bedside imaging and supporting future advances in AI-assisted neurosurgical care. The ClearFit AI™ platform combi

ENvue Medical, Inc. (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced the successful development and demonstration of the first prototype of ENvue Drive™, which the Company believes is the first next-generation robotic-assisted tool built within the ENvue electromagnetic navigation platform ecosystem, designed to integrate ar

Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already ad

Miach Orthopaedics, Inc., a company transforming the treatment of anterior cruciate ligament (ACL) tears from reconstruction to restoration with the Bridge-Enhanced ACL Restoration (BEAR®) Implant, today announced it will present two-year outcomes from the first 200 patients enrolled in the Bridge Registry at the American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting, July 8-11 in Seattle. The presentation will highlight how evolved fixation and suture technique

Novartis today announced that the European Commission (EC) has approved Itvisma® (onasemnogene abeparvovec) for the treatment of children two years and older, teens and adults living with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene. With this approval, Itvisma becomes the first and only gene replacement therapy currently approved for this broad SMA population in the European Union. Itvisma is uniquely designed